Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)

NAD+: Evidence Summary

Name: NAD+ Evidence Summary — Clinical Trial Data
Published: 2026-03-12

Evidence summary for NAD+ across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.

Back to NAD+ overview

Indication	Evidence Tier	Trial Count	Summary
Cellular aging	Tier B	8	Growing human trial evidence for NMN/NR supplementation
Energy metabolism	Tier B	6	Consistent improvements in mitochondrial function markers
Neuroprotection	Tier C	5	Preclinical data strong, human data emerging